These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26284306)

  • 1. The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
    Chen B; Xu M; Zhang H; Xu MZ; Wang XJ; Tang QH; Tang JY
    DNA Cell Biol; 2015 Oct; 34(10):610-7. PubMed ID: 26284306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
    Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
    Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
    Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells.
    Lou HZ; Weng XC; Pan HM; Pan Q; Sun P; Liu LL; Chen B
    Biochem Biophys Res Commun; 2014 Jul; 450(2):973-8. PubMed ID: 24971544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
    Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH
    Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
    Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH
    Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.
    Srivastava RK; Li C; Khan J; Banerjee NS; Chow LT; Athar M
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24583-24592. PubMed ID: 31732667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.
    Wang L; Zhu YR; Wang S; Zhao S
    Tumour Biol; 2016 Sep; 37(9):11743-11752. PubMed ID: 27020593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
    Jiang H; Zeng Z
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes.
    Chen J; Liu K; Liu Y; Wang X; Zhang Z
    Exp Dermatol; 2019 Mar; 28(3):270-275. PubMed ID: 30650200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
    Xin Y; Shen XD; Cheng L; Hong DF; Chen B
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):711-9. PubMed ID: 24519751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoplasmic reticulum stress sensitizes human esophageal cancer cell to radiation.
    Pang XL; He G; Liu YB; Wang Y; Zhang B
    World J Gastroenterol; 2013 Mar; 19(11):1736-48. PubMed ID: 23555162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
    Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
    Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
    Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.
    Jiang SJ; Wang S
    Tumour Biol; 2015 Sep; 36(10):8177-84. PubMed ID: 25990456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.